The shortage of stimulant-based ADHD (Attention Deficit Hyperactivity Disorder) medications like Adderall, Vyvanse and Ritalin persists, with leading drug makers unable to provide a solution.

The shortage began in Fall 2022 and was exacerbated by record-high prescription rates.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), the largest manufacturer of Adderall, cites COVID-induced work shortages as a reason for decreased production and remains reluctant to increase output due to infrastructure limitations.

In 2021, they produced 565 million Adderall tablets, but demand continues to outstrip supply, reported Bloomberg.

ADHD Medication Shortage And Urgent FDA/DEA Action

The American Society of Health-System Pharmacists reports shortages in 141 ADHD medication doses or formulations, with few estimated resolution dates, expecting some availability in mid-October.

The FDA and DEA jointly acknowledged the issue in August, urging drug makers to boost production, but no resolution date was provided.

Manufacturers only sold 70% of their allotted quota, equating to a billion doses not produced or sold. Meanwhile, the FDA and DEA call on stakeholders to ensure responsible access to stimulant …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.